IP Library › Granted Patent US 8,765,385
Granted Patent B2
US 8,765,385 · App. 13/283,552 · Granted Jul 1, 2014

Method of detection of neutralizing anti-actriib antibodies

Inventors: Ravindra Kumar (Acton, MA); Asya Grinberg (Lexington, MA); Monique Davies (Harpswell, ME); Diana Martik (Cambridge, MA); Janja Cosic (Arlington, MA); Rachel Kent (Boxborough, MA); David Buckler (Chester, NJ)
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,765,385
App. No.
13/283,552
Granted
Jul 1, 2014
Kind
B2
Abstract

The disclosure provides, among other aspects, neutralizing antibodies and portions thereof that bind to ActRIIB and uses for same.

Claims (18)

1. A method for detecting in a sample the presence of a neutralizing anti-ActRIIB antibody, the method comprising:

(i) forming a mixture comprising the sample, an ActRIIB polypeptide and a control antibody that is a known neutralizing, monoclonal anti-ActRIIB antibody, wherein the anti-ActRIIB antibody comprises:

a) a light chain comprising:

i) a CDR1 comprising the amino acid sequence of SEQ ID NO:40;

ii) a CDR2 comprising the amino acid sequence of SEQ ID NO:41; and

iii) a CDR3 comprising the amino acid sequence of SEQ ID NO:42; and

b) a heavy chain comprising:

i) a CDR1 comprising the amino acid sequence of SEQ ID NO:37;

ii) a CDR2 comprising the amino acid sequence of SEQ ID NO:38; and

iii) a CDR3 comprising the amino acid sequence of SEQ ID NO:39; and

(ii) measuring the amount of control antibody that is bound to the ActRIIB polypeptide, wherein the ActRIIB polypeptide is a polypeptide comprising a ligand-binding domain of ActRIIB, and wherein a decrease in the amount of control antibody bound to the ActRIIB polypeptide relative to a standard indicates that the sample contains a neutralizing anti-ActRIIB antibody.

2. The method of claim 1 , wherein the standard is a mixture comprising the ActRIIB polypeptide, and the control antibody.

3. The method of claim 1 , wherein the standard comprises a sample that is known to contain no substantial amount of neutralizing anti-ActRIIB antibody.

4. The method of claim 1 , wherein the standard comprises a sample that contains a known amount of neutralizing anti-ActRIIB antibody.

5. The method of claim 1 , wherein the sample contains blood or a blood product.

6. The method of claim 5 , wherein the sample contains blood or a blood product from a patient treated with an ActRIIB-Fc fusion protein.

7. The method of claim 1 , wherein the standard comprises a sample that contains blood or a blood product from a human patient that has not been treated with an ActRIIB-Fc fusion protein.

8. The method of claim 1 , wherein the neutralizing anti-ActRIIB is Ab-17G05.

Continuity (1)
Related Publication 20130108650A1 · May 2, 2013